Correlation of haloperidol levels between saliva and plasma of acutely ill schizophrenic patients.

Autor: Jain T; Faculty of Pharmaceutical Sciences, Jodhpur National University, Jodhpur-342001 (Rajasthan), India. jain0291@gmail.com, Bhandari A, Ram V, Sharma S, Parakh M, Parakh MC
Jazyk: angličtina
Zdroj: Clinical biochemistry [Clin Biochem] 2011 Jun; Vol. 44 (8-9), pp. 675-80. Date of Electronic Publication: 2011 Mar 31.
DOI: 10.1016/j.clinbiochem.2011.03.135
Abstrakt: Objective: Clinical usefulness of monitoring haloperidol in salivary samples based on plasma:saliva correlation.
Design and Methods: Plasma and saliva samples of schizophrenic patients [N=105] were analyzed by highly sensitive reverse phase liquid chromatographic method to measure haloperidol at 240 nm using UV-PDA detector. Mobile phase consist of acetonitrile and water [50:50], pH 2.5 (0.1% acetic acid and 0.05 M KHPO(4)) at flow rate 1.4 mL/min. Method was linear over 3-200 ng/mL.
Results: Observed therapeutic range was 5-19 ng/mL [11.66±3.97] and 17-54 ng/mL [27.52±11.51] for plasma and saliva respectively. Mean S:P was found to be 2.36.
Conclusion: Current study showed significantly high correlation [r=0.93, p<0.0001] between haloperidol levels in saliva and plasma with linear relationship. It is therefore concluded that monitoring of salivary concentration can be a clinically beneficial substitute. Patients showing clinical improvement [N=90] were within salivary concentration range of 17-54 ng/mL, which can be an appropriate steady state monitoring range for haloperidol in saliva.
(Copyright © 2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: